These results were sufficiently compelling to justify a tumor agnostic accelerated FDA approval for T-DXd for the treatment of unresectable or metastatic HER2 (3+ by IHC)-positive solid tumors, including urothelial cancers. The gene discussed is ERBB2; the disease is neoplasm.